Earnings Call Excerpt
Celgene Corporation (CELG)
Q4 2005 Earnings Conference Call
January 26th 2006, 9:00 AM.
Executives:
Robert Hugin, Chief Financial Officer, Senior Vice President, Director
Sol Barer, President, Chief Operating Officer and Director
John Jackson, Chairman of the Board, Chief Executive Officer
Analysts:
Ian Somaiya, Thomas Weisel Partner
Geoff Meacham, JP Morgan
Lei Zhong, Banc of America
Gerald Weber, Citigroup
Charles Duncan, JMP Security
Jim Reddoch, FBR
Sapna Srivastava, Morgan Stanley
Matt Osborne, Lazard
Presentation
Operator
My name is Joseph and I will be your conference facilitator today. At this time I would like to welcome everyone to the Celgene’s Quarterly Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks there will be a question and answer session. Operator Instruction Now I would like to turn the call over to Mr. Bob Hugin, thank you sir you may begin.
Robert Hugin, Chief Financial Officer, Senior Vice President, Director
Thank you and good morning. I am Bob Hugin, Celgene’s Chief Financial Officer and thank you for joining us today. With me are John Jackson, our Chairman and Chief Executive Officer; and Sol Barer, Celgene’s President and Chief Operating Officer.
Before we begin I will review our Safe Harbor statement. Certain statements made during this conference call maybe forward-looking and are made pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995. Certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under our control may cause actual results, performance and achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include the results of current or pending clinical trials or products failure to demonstrate efficacy or an acceptable safety profile actions by the FDA, the financial conditional of suppliers including their solvency and ability to supply product and other factors detailed in our filings with the Securities and Exchange Commission are referred to in the press release issued this morning.
2005 was an extraordinary year, a transforming year for Celgene culminated by the approval of Revlimid in the last week of December. Our highest corporate priority for 2005 was the acceleration of key Revlimid clinical and regulatory programs. The significance of the data produced in multiple major clinical trials and the subsequent FDA approval positions us favorably for the accomplishment of our key 2006 corporate objectives, which were highlighted by the successful commercial launch of Revlimid in the United States.
- To read the full transcript on Seeking Alpha, click here »
